Q-omics provides the consensus-scored PROM1 profile across patient tissues and cancer cell-line models. PROM1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PROM1 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, PROM1 RNA expression shows 17,079 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, KIRC, and THYM as cancer lineages where PROM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PROM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PROM1 survival associations across molecular data types. PROM1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PROM1 RNA expression–survival associations across cancer types. High PROM1 expression shows unfavorable associations in LGG, SKCM and BLCA, but favorable associations in KIRP, LUAD and STAD. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PROM1 RNA expression.
This table summarizes PROM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PROM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PROM1 shows lower tumor expression in KIRC, KICH, THCA, BRCA and KIRP and higher tumor expression in UCEC. The KIRC box plot shows higher PROM1 RNA expression in normal versus tumor tissue (log2 FC = −3.866, t-test p < 0.001).
This table shows molecular features associated with PROM1 in patient tissues and cancer cell lines. In patient samples, PROM1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PROM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LUNG_SCLC.
